PRAVASTATIN IN CORRECTION OF VESSEL WALL ANTIPLATELET CONTROL OVER THE BLOOD CELLS IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA

Abstract

Aim. To evaluate in patients with arterial hypertension (AH) and dyslipidemia (DL) a grade of correction influence of pravastatin on antiaggregation activity of vessel wall for erythrocytes, platelets and leukocytes.Material and methods. Totally 47 patients observed with 1-2 levels of AH and the risk 3, with DL IIb type, middle age. Controls were 26 healthy people of the same age. To correct DL all patients were prescribed pravastatin 20 mg before night sleep with already being taken enalapril 10 mg BID. Chemistry, blood count and statistics used. Evaluation of clinical and laboratory parameters was performed in the beginning of treatment, in 4, 12 and 52 weeks.Results. An enforced in AH with DLP erythrocyte, platelet neutrophil aggregation was linked with a control decrease over it by vessel wall and as result of lipid metabolism changes, peroxide oxydation of plasma lipids, lowering of NO generation and of prostacycline as well. After 52-week use of pravastatine in AH with DLP there was significantly better in lipid profile and there was weakening of peroxidation of lipids in plasma, that followed by significant positive dynamics of antiplatelet properties of vessel wall.Conclusion. In AH patients with DLP there is weakening of antiplatlet control by vessels over blood cells, which becomes slightly improved after 52-week pravastatine treatment.

Keywords

• артериальная гипертония
• дислипидемия
• правастатин
• антиагрегационная активность сосудистой стенки
• клетки крови